Starpharma Holdings Company Description
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide.
The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating.
It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.
In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel; and DEP HER2 radiodiagnostic.
It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma’s dendrimer technology.
Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
| Country | Australia |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Cheryl Maley |
Contact Details
Address: 4-6 Southampton Crescent Abbotsford, 3067 Australia | |
| Phone | 61 3 8532 2700 |
| Website | starpharma.com |
Stock Details
| Ticker Symbol | SPHRF |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000SPL0 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Cheryl Maley | Chief Executive Officer |
| Justin Cahill | Chief Financial Officer |